Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04797221 · ClinicalTrials.gov registry record
Emergency Room Firearm and Medication Safety Intervention
A clinical trial, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- 28
- Enrollment target
NCT04797221: Completed study, sponsored by VA Office of Research and Development.
NCT04797221 is a clinical trial that has completed, run by VA Office of Research and Development. The registered enrollment target is 28 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04797221 has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- 28 participants
- Enrollment target
Study Summary
Seventeen United States Veterans die by suicide each day. Nearly three-fourths of those Veterans die from firearm injury or poisoning, and many seek care in VA Emergency Departments (ED) prior to suicide attempts. In 2019, the VA began screening all Veterans seeking ED care for increased suicide risk. Interventions that promote firearm and medication safety are recommended for Veterans identified as at-risk. The investigators work will provide important information that will aid the development and testing of such an intervention for Veterans who seek care in VA EDs. The investigators will interview at-risk Veterans who recently sought VA ED care to identify factors relevant to developing the intervention, and work with Veterans and VA healthcare staff to develop and test an intervention.
Primary Outcome
Perspectives on VA-based interventions that aim to reduce access to firearms and medications.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2021-07-01 |
| Est. Completion | 2023-02-16 |
What the finished NCT04797221 record still lists
NCT04797221 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 28 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT04797221 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04797221 about?
NCT04797221 is a clinical study titled "Emergency Room Firearm and Medication Safety Intervention". Seventeen United States Veterans die by suicide each day. Nearly three-fourths of those Veterans die from firearm injury or poisoning, and many seek care in VA Emergency Departments (ED) prior to suicide attempts. In 2019, the VA began screening all Veterans seeking ED care for increased suicide ris...
What is the current status of trial NCT04797221?
This trial is currently completed. The enrollment target is 28 participants. The study started on 2021-07-01. Estimated completion is 2023-02-16.
Who is sponsoring clinical trial NCT04797221?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI